Compare ADMA Biologics Inc (ADMA) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs KKR & Co Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while KKR & Co Inc trades at $110.59 (market cap $99.61B). The key difference: KKR & Co Inc is far larger — about 44.9× ADMA Biologics Inc's market cap, and KKR & Co Inc pays a 0.7% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | KKR | |
|---|---|---|
Market Cap | $2.22B | $99.61B |
Sector | Health | Financials |
52-Week High | $20.38 | $149.34 |
52-Week Low | $7.60 | $83.88 |
Enterprise Value | $2.29B | $22.17B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
KKR trades at $110.625, up 6.54% today, with strong bullish momentum near its consensus price target of $127.22. Recent earnings beats in Q1 and Q2 2026, alongside a high analyst buy rating of 88.89%, reflect robust operational performance. The company's strategic acquisitions, including Medicover India and Integer Holdings, signal aggressive growth in healthcare and infrastructure sectors.
The outlook for KKR is positive, driven by earnings growth and strategic expansions, but risks include high leverage and market volatility. Upside potential exists if the company maintains its earnings trajectory and executes acquisitions successfully, though investors should monitor debt levels and integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
